BIOMAT Database Logo BIOMAT Database Logo

Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. 1996

K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
Second Department of Surgery, School of Medicine, Nagoya University, Japan.

BACKGROUND A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection. METHODS The patients were divided into two groups, a control group receiving no HCFU and a group administered HCFU for 1 year, using a centralized registration system by telephone. Among 173 patients entered into this study, 159 evaluable cases were analyzed for evaluation of the drug. RESULTS The cumulative 5-year disease-free rate of patients who received HCFU was significantly increased compared with the control group. In particular, the rate was much higher in patients with colon cancer. No severe side effects arose from adjuvant chemotherapy with HCFU. CONCLUSIONS Adjuvant chemotherapy with oral HCFU appears to provide a useful and safe postoperative treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal

Related Publications

K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Prospective adjuvant chemotherapy of mitomycin C plus HCFU for colorectal cancer (2d report)--6-year survival after surgery: Tokai Cooperative Study Group of Surgical Adjuvant Chemotherapy].
April 1988, Gan no rinsho. Japan journal of cancer clinics,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III.
August 2001, International journal of oncology,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five-year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
March 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal cancer].
January 2004, Gan to kagaku ryoho. Cancer & chemotherapy,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
Mitomycin C plus carmofur (HCFU) adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma (interim report).
September 1987, The Japanese journal of surgery,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer].
February 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (third report): five-year results after surgery].
January 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[The determination of thymidylate synthetase inhibition for testing fluoropyrimidines--pharmacokinetics and metabolism of carmofur (HCFU) in patients with gynecologic malignancies--Tokai HCFU Study Group for Gynecologic Malignancies].
November 1986, Gan no rinsho. Japan journal of cancer clinics,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study].
November 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
K Ito, and A Yamaguchi, and K Miura, and T Kato, and S Baba, and S Matsumoto, and M Ishii, and H Takagi
[Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma. (Second report): 5-year survival rate. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy].
March 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!